Alethia Young

CIK 1918147 · View on SEC EDGAR ↗

Insider

First SEC filing: June 12, 2026 · Latest: June 12, 2026

On this page

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 16 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
June 10, 2026 PCRX A 10,891 10,891 Direct Acquired (price as of 2026-08-20)
June 10, 2026 PCRX A 6,405 17,798 Direct +56.22% Acquired (price as of 2026-08-20)
June 11, 2025 PCRX A 6,163 11,393 Direct +117.84% Acquired (price as of 2026-08-20)
June 11, 2025 PCRX A 11,279 11,279 Direct Acquired (price as of 2026-08-20)
June 12, 2024 PCRX A 5,230 5,230 Direct Acquired (price as of 2026-08-20)
June 12, 2024 PCRX A 12,179 12,179 Direct Acquired (price as of 2026-08-20)
Jan. 2, 2024 BCYC A 24,000 24,000 Direct Acquired (price as of 2026-08-20)
Jan. 2, 2024 BCYC A 12,000 12,000 Direct Acquired (price as of 2026-08-20)
Oct. 6, 2023 PCRX A 30,967 30,967 Direct Acquired (price as of 2026-08-20)
July 17, 2023 BCYC A 120,000 120,000 Direct Acquired (price as of 2026-08-20)
Feb. 21, 2023 LENZ A 220,000 220,000 Direct Acquired (price as of 2026-08-20)
June 9, 2022 PTCT A 3,200 3,200 Direct Acquired (price as of 2026-08-20)
June 9, 2022 PTCT A 1,867 5,067 Direct +58.34% Acquired (price as of 2026-08-20)
June 9, 2022 PTCT A 12,000 12,000 Direct Acquired (price as of 2026-08-20)
June 9, 2022 PTCT A 7,000 7,000 Direct Acquired (price as of 2026-08-20)
April 1, 2022 LENZ A 350,000 350,000 Direct Acquired (price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date Ticker Security Underlying Exercise price Expiration Shares A/D
June 10, 2026 PCRX Stock Option (Right to Buy) Common Stock (10,891) $23.42 June 10, 2036 10,891 Acquired
June 11, 2025 PCRX Stock Option (Right to Buy) Common Stock (11,279) $24.34 June 11, 2035 11,279 Acquired
June 12, 2024 PCRX Stock Option (Right to Buy) Common Stock (12,179) $28.68 June 12, 2034 12,179 Acquired
Jan. 2, 2024 BCYC Employee Stock Option (right to buy) Ordinary Shares (24,000) $18.08 Jan. 2, 2034 24,000 Acquired
Oct. 6, 2023 PCRX Stock Option (Right to Buy) Common Stock (30,967) $29.80 Oct. 6, 2033 30,967 Acquired
July 17, 2023 BCYC Employee Share Option (Right to Buy) Ordinary Shares (120,000) $26.21 July 17, 2033 120,000 Acquired
Feb. 21, 2023 LENZ Stock Option (right to buy) Common Stock (220,000) $2.18 Feb. 20, 2033 220,000 Acquired
June 9, 2022 PTCT Stock Option (Right to Buy) Common Stock (12,000) $27.85 June 8, 2032 12,000 Acquired
June 9, 2022 PTCT Stock Option (Right to Buy) Common Stock (7,000) $27.85 June 8, 2032 7,000 Acquired
April 1, 2022 LENZ Stock Option (right to buy) Common Stock (350,000) $5.23 March 31, 2032 350,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2022 $337,500 $170,000 $1,212,715 $115,274 $151,350 $1,835,489

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.